Flush with cash, BMS chief confirms '100% pharma' focus

Bristol-Myers Squibb ($BMY) CEO Lamberto Andreotti (photo) is happy he has $10 billion in cash to spend on small acquisitions that can bolster his pure-pharma strategy. He's especially happy most of it is already in the U.S., rather than subject to repatriation taxes. Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.